In AMPECT, most treatment-related adverse reactions were Grade 1 or 21

  • 65% of patients required no dose reduction; 35% of patients required a dose reduction due to an adverse reaction
  • —  

    The most common reasons for dose reductions were mucositis and pneumonitis1

  • 65% of patients had a dose interruption due to an adverse reaction
  • Three patients (9%) discontinued treatment due to an adverse reaction (pneumonitis, anemia, and noninfective cystitis)

*

Permanently discontinue FYARRO in patients who are unable to tolerate FYARRO after 3 dose reductions.

In the AMPECT study, stomatitis was the most common adverse reaction with FYARRO. Supportive care measures, including use of steroid mouthwash and/or other oral treatments were permitted during the study2

In the AMPECT study, stomatitis was the most common adverse reaction with FYARRO. Supportive care measures, including use of steroid mouthwash and/or other oral treatments were permitted during the study2

AMPECT=Advanced Malignant PEComa Trial.

References: 1. Wagner AJ, Ravi V, Riedel RF, et al. nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors. J Clin Oncol. 2021;39(33):3660-3670. doi:10.1200/JCO.21.01728 2. Data on file. Aadi Bioscience, Inc.; 2021.